JPMorgan analyst Anupam Rama initiated coverage of Syndax with an Overweight rating and $41 price target. The Overweight rating is predominantly driven by revumenib in acute leukemias, which is "de-risked" and has "best-in-class potential, based on known data to date," Rama tells investors in a research note. The analyst’s peak sales estimate for revumenib is $1.3B in the refractory setting alone.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- Barclays views GSK acquisition interest as positive for oncology stocks
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Syndax price target raised to $33 from $31 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- Syndax 6.82M share Spot Secondary priced at $22.00